BETHESDA, Md., Jul 22, 2008 (BUSINESS WIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that
Andrew J. Ferrara, 68, chairman and chief executive officer of Boston
Healthcare Associates, Inc., has been appointed to Sucampo
Pharmaceuticals' Board of Directors effective July 16, 2008. Mr.
Ferrara has also been named a member of the Board's Compensation
Committee.

Mr. Ferrara spent the first 20 years of his career with Eli Lilly
& Company (NYSE: LLY), a leading pharmaceutical company, where he held
a number of positions in the United States and Europe in business
areas, including sales and sales management, marketing, public
relations and new product planning and licensing. Following Eli Lilly,
Mr. Ferrara served as group vice president of sales and marketing at
Collaborative Research, Inc. and in 1984 he co-founded Polygen
Corporation, a computer software company focused on the chemical and
pharmaceutical research industries. At Polygen, Mr. Ferrara was
responsible for business development, sales and product development.
He initiated a number of research and licensing agreements with
academic institutions and major healthcare corporations in the United
States, Europe and Japan. In 1993, Mr. Ferrara founded Boston
Healthcare Associates, Inc., a healthcare consulting company. He has
also been involved in the development of a variety of public and
private companies.

"Andy's diverse knowledge and experience in commercialization,
product licensing and business development will be an invaluable
resource for Sucampo as we pursue global expansion of our own product,
AMITIZA(R), to Europe and other countries and as we seek to maximize
our pipeline of prostone compounds," said Ryuji Ueno, M.D., Ph.D.,
Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer.
"We are delighted to welcome him to the Board."

"I am pleased to join Sucampo Pharmaceuticals' Board and look
forward to contributing to furthering the company's success as it
expands its international presence and considers future in-licensing
and out-licensing opportunities," said Mr. Ferrara.

In addition to Sucampo Pharmaceuticals, Mr. Ferrara currently
serves on the Board of Directors of Indevus Pharmaceuticals, Inc.
(NASDAQ: IDEV), a biopharmaceutical company, and the Board of Trustees
of Franklin Pierce Law Center and is a member of the corporation of
the Woods Hole Oceanographic Institute, a nonprofit ocean research,
engineering and education organization.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical
company based in Bethesda, Md., focuses on the development and
commercialization of medicines based on prostones. The therapeutic
potential of prostones, which are bio-lipids that occur naturally in
the human body, was first identified by Ryuji Ueno, M.D., Ph.D.,
Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer.
Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno,
Ph.D., founding Chief Executive Officer and advisor, international
business development.

Sucampo Pharmaceuticals is marketing AMITIZA(R) (lubiprostone) 24
mcg in the U.S. for chronic idiopathic constipation in adults and
AMITIZA(R) (lubiprostone) 8 mcg in the U.S. to treat irritable bowel
syndrome with constipation in adult women and is developing the drug
for additional gastrointestinal disorders with large potential
markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of
compounds with the potential to target unmet medical conditions
affecting millions of patients worldwide. Sucampo Pharmaceuticals has
two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd.,
headquartered in Oxford, UK with a branch office in Basel,
Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka,
Japan. To learn more about Sucampo Pharmaceuticals and its products,
visit www.sucampo.com.

Forward-Looking Statements

Any statements in this press release about future expectations,
plans and prospects for Sucampo Pharmaceuticals are forward-looking
statements made under the provisions of The Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be
identified by the words "project," "believe," "anticipate," "plan,"
"expect," "estimate," "intend," "should," "would," "could," "will,"
"may" or other similar expressions. Actual results may differ
materially from those indicated by such forward-looking statements as
a result of various important factors described in Sucampo
Pharmaceuticals' filings with the Securities and Exchange Commission
(SEC), including the annual report on Form 10-K for the year ended
December 31, 2007 and other periodic reports filed with the SEC. Any
forward-looking statements in this press release represent Sucampo
Pharmaceuticals' views only as of the date of this release and should
not be relied upon as representing its views as of any subsequent
date. Sucampo Pharmaceuticals anticipates that subsequent events and
developments will cause its views to change. However, while Sucampo
Pharmaceuticals may elect to update these forward-looking statements
publicly at some point in the future, Sucampo Pharmaceuticals
specifically disclaims any obligation to do so, whether as a result of
new information, future events or otherwise.

AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals,
Inc.

SOURCE: Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.
Mariam E. Morris, 301-961-3400
Chief Financial Officer
mmorris@sucampo.com

Copyright Business Wire 2008